Dipeptidyl peptidase-4 inhibitors, also known as gliptins, are a modern class of oral hypoglycemic agents used in the management of type 2 diabetes mellitus (T2DM). These drugs work by enhancing the body’s own incretin system, improving glucose-dependent insulin secretion while suppressing glucagon release. DPP-4 inhibitors are known for their glycemic efficacy with a low risk of hypoglycemia and a neutral effect on weight, making them especially suitable for elderly and overweight patients with T2DM.
1. Mechanism of Action
DPP-4 is a ubiquitous serine protease enzyme responsible for rapid degradation of incretin hormones, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These incretins are secreted in response to nutrient intake and act to:
-
Increase glucose-dependent insulin secretion
-
Decrease glucagon secretion
-
Delay gastric emptying
-
Promote satiety
By inhibiting DPP-4, gliptins extend the half-life of endogenous incretins, enhancing their physiological effects on glucose homeostasis.
2. List of Generic Drugs (and Select Brand Names)
| Generic Name | Common Brand Names |
|---|---|
| Sitagliptin | Januvia |
| Saxagliptin | Onglyza |
| Linagliptin | Tradjenta |
| Alogliptin | Nesina |
| Vildagliptin | Galvus (not FDA approved in US) |
| Teneligliptin | Available in Asia (not US) |
| Gemigliptin | South Korea, Asia markets |
3. Approved Indications
-
Type 2 Diabetes Mellitus (as monotherapy or in combination with metformin, sulfonylureas, thiazolidinediones, SGLT-2 inhibitors, or insulin)
4. Dosing Guidelines
| Drug | Standard Dose | Renal Adjustments |
|---|---|---|
| Sitagliptin | 100 mg once daily | 50 mg (eGFR 30–50), 25 mg (<30 mL/min) |
| Saxagliptin | 5 mg once daily | 2.5 mg (eGFR ≤ 50 or on dialysis) |
| Linagliptin | 5 mg once daily | No adjustment required |
| Alogliptin | 25 mg once daily | 12.5 mg (eGFR 30–59), 6.25 mg (<30 mL/min) |
| Vildagliptin | 50 mg twice daily | Not approved in the US |
5. Clinical Benefits
-
Effective HbA1c reduction (~0.5% to 1%)
-
Low risk of hypoglycemia (when not combined with sulfonylureas/insulin)
-
Weight-neutral
-
Safe in the elderly
-
Cardiovascular safety (CVOTs confirm non-inferiority)
6. Contraindications
-
Type 1 diabetes mellitus
-
Diabetic ketoacidosis
-
Hypersensitivity to the drug or its components
-
History of serious hypersensitivity reactions (e.g., angioedema, anaphylaxis)
7. Adverse Effects
| Category | Reported Effects |
|---|---|
| Gastrointestinal | Nausea, diarrhea, abdominal pain |
| Dermatologic | Rash, urticaria, exfoliative skin reactions |
| Musculoskeletal | Arthralgia, back pain |
| Immunologic | Hypersensitivity, angioedema |
| Metabolic | Hypoglycemia (when combined with sulfonylurea) |
| Pancreatic | Rare reports of pancreatitis |
| Cardiovascular | Saxagliptin: may increase risk of heart failure hospitalization (SAVOR-TIMI 53 trial) |
8. Cardiovascular and Renal Outcomes
-
TECOS Trial (Sitagliptin): No increase in CV risk
-
SAVOR-TIMI 53 (Saxagliptin): ↑ Risk of heart failure hospitalization
-
EXAMINE Trial (Alogliptin): No CV benefit or harm
-
CARMELINA Trial (Linagliptin): No CV or renal harm
DPP-4 inhibitors are not cardioprotective like SGLT-2 inhibitors or GLP-1 receptor agonists but are considered cardiovascularly safe except for potential risks with saxagliptin.
9. Drug Interactions
| Interacting Agent | Outcome or Mechanism |
|---|---|
| Sulfonylureas | Additive risk of hypoglycemia |
| Insulin | Risk of hypoglycemia |
| Rifampin (with linagliptin) | Reduced exposure due to CYP induction |
| Strong CYP3A4 inhibitors | Affects saxagliptin metabolism |
| ACE inhibitors | May enhance risk of angioedema |
10. Advantages Over Other Oral Antidiabetics
| Characteristic | DPP-4 Inhibitors | Sulfonylureas | Metformin |
|---|---|---|---|
| Hypoglycemia Risk | Low | High | Low |
| Weight Impact | Neutral | Weight gain | Neutral or loss |
| Tolerability | Well-tolerated | Hypoglycemia common | GI intolerance |
| Cardiovascular Safety | Neutral | Uncertain | Benefit in UKPDS |
| Renal Safety | Adjusted dosing needed | Adjusted or avoided | Avoid if eGFR <30 |
11. Use in Special Populations
Elderly:
-
Well tolerated; minimal hypoglycemia
-
Linagliptin ideal due to no renal adjustment
Renal Impairment:
-
Linagliptin preferred; others require dose reduction
Hepatic Impairment:
-
Caution with saxagliptin (CYP metabolism)
-
Linagliptin: safe in mild-to-moderate hepatic dysfunction
Pregnancy & Lactation:
-
Not recommended due to limited human data
Pediatrics:
-
Not approved under 18 years of age
12. Role in Therapy (ADA/EASD Guidelines)
According to the American Diabetes Association (ADA) Standards of Care 2024, DPP-4 inhibitors are:
-
Suitable for patients not at high risk of ASCVD, HF, or CKD
-
Considered add-on to metformin when cost is not a primary barrier
-
Not preferred if GLP-1 receptor agonists or SGLT2 inhibitors are accessible and tolerated in patients with comorbidities
13. Summary of Clinical Recommendations
-
Initiate as monotherapy in patients intolerant to metformin or with contraindications
-
Use as dual therapy with metformin if target HbA1c not reached after 3 months
-
Triple therapy combinations include DPP-4 inhibitors with metformin + sulfonylureas or insulin
-
Avoid combining with GLP-1 agonists (same incretin pathway → redundancy)
-
Monitor for signs of pancreatitis and hypersensitivity
-
Adjust dose based on renal function except with linagliptin
No comments:
Post a Comment